CN105008539B - 通过酶缀合在大肠杆菌中生产重组疫苗 - Google Patents

通过酶缀合在大肠杆菌中生产重组疫苗 Download PDF

Info

Publication number
CN105008539B
CN105008539B CN201380069524.XA CN201380069524A CN105008539B CN 105008539 B CN105008539 B CN 105008539B CN 201380069524 A CN201380069524 A CN 201380069524A CN 105008539 B CN105008539 B CN 105008539B
Authority
CN
China
Prior art keywords
gram
coli
streptococcus pneumoniae
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380069524.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105008539A (zh
Inventor
M.瓦克
M.科瓦里克
M.韦特
A.法里德莫亚耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Glycovaxyn AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, Glycovaxyn AG filed Critical GlaxoSmithKline Biologicals SA
Publication of CN105008539A publication Critical patent/CN105008539A/zh
Application granted granted Critical
Publication of CN105008539B publication Critical patent/CN105008539B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201380069524.XA 2012-11-07 2013-11-07 通过酶缀合在大肠杆菌中生产重组疫苗 Expired - Fee Related CN105008539B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723408P 2012-11-07 2012-11-07
US61/723408 2012-11-07
PCT/EP2013/073266 WO2014072405A1 (en) 2012-11-07 2013-11-07 Production of recombinant vaccine in e. coli by enzymatic conjugation

Publications (2)

Publication Number Publication Date
CN105008539A CN105008539A (zh) 2015-10-28
CN105008539B true CN105008539B (zh) 2020-04-17

Family

ID=49552366

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380069524.XA Expired - Fee Related CN105008539B (zh) 2012-11-07 2013-11-07 通过酶缀合在大肠杆菌中生产重组疫苗

Country Status (16)

Country Link
US (2) US20150273043A1 (enExample)
EP (3) EP3444352B1 (enExample)
JP (2) JP6412875B2 (enExample)
KR (1) KR20150079964A (enExample)
CN (1) CN105008539B (enExample)
AU (2) AU2013343520B2 (enExample)
BR (1) BR112015010283A8 (enExample)
CA (2) CA2889767C (enExample)
EA (1) EA201590705A1 (enExample)
ES (3) ES2713166T3 (enExample)
IL (1) IL238586A0 (enExample)
MX (1) MX366912B (enExample)
SG (1) SG11201503308XA (enExample)
TR (1) TR201903066T4 (enExample)
WO (1) WO2014072405A1 (enExample)
ZA (1) ZA201503097B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010322454B2 (en) * 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
US11220676B2 (en) * 2013-10-11 2022-01-11 Glaxosmithkline Biological Sa Methods of host cell modification
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
SI3131577T1 (sl) * 2014-04-17 2020-08-31 Glaxosmithkline Biologicals S.A. Modificirane gostiljske celice in uporabe le-teh
SG11201700325SA (en) * 2014-08-08 2017-02-27 Glycovaxyn Ag Modified host cells and hybrid oligosaccharides for use in bioconjugate production
AU2016224006B8 (en) * 2015-02-26 2020-03-19 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
CN105963691B (zh) * 2016-07-03 2020-05-01 查文娟 一种肺炎链球菌疫苗
CN106929573B (zh) * 2017-02-21 2020-06-09 南开大学 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用
GB201712678D0 (en) * 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
WO2019090138A2 (en) * 2017-11-04 2019-05-09 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Immunogenic conjugates and methods of use thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019241672A2 (en) 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3650044A1 (en) * 2018-11-06 2020-05-13 ETH Zürich Anti-glycan vaccines
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
CN112369722B (zh) * 2020-05-08 2023-03-17 湖北中烟工业有限责任公司 加热不燃烧装置和温度控制方法
CN111518738B (zh) * 2020-05-08 2022-02-08 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
CA3185719A1 (en) * 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
US20230293657A1 (en) 2020-06-25 2023-09-21 Glaxosmithkline Biologicals Sa Vaccine
KR20230043157A (ko) 2020-09-17 2023-03-30 얀센 파마슈티칼즈, 인코포레이티드 다가 백신 조성물 및 이의 용도
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948900A (en) * 1994-05-16 1999-09-07 Uab Research Foundation Streptococcus pneumoniae capsular polysaccharide genes and flanking regions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
JP5356807B2 (ja) 2005-05-11 2013-12-04 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えｎ−グリコシル化タンパク質
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
CA2756170C (en) * 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
KR20120085240A (ko) 2009-07-17 2012-07-31 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합
ES2844596T3 (es) 2010-05-06 2021-07-22 Glaxosmithkline Biologicals Sa Vacunas de bioconjugados de bacterias grampositivas capsulares
TR201904022T4 (tr) * 2012-10-12 2019-04-22 Glaxosmithkline Biologicals Sa Konakçı hücre modifikasyon yöntemleri.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948900A (en) * 1994-05-16 1999-09-07 Uab Research Foundation Streptococcus pneumoniae capsular polysaccharide genes and flanking regions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
molecular organization of the genes required for the synthesis of type1 capsular polysaccharide of Streptococcus pneumoniae:formation of binary encapsulated pneumococci and identification of cryptic dTDP-rhamnose biosynthesis genes;Rosari Munoz;《Microbial cell Factories 》;19971231;摘要 *
N-Linked Glycosylation in Campylobacter jejuni and Its Functional Transfer into E.coli;Michael Wacker;《Science》;20021129;摘要 *
Production of glycoprotein vaccine in Escherichia Coli;Julian Ihssen et al;《Microbial cell Factories 》;20101231;摘要，第2页-第3页的跨页段 *

Also Published As

Publication number Publication date
EP3444352A3 (en) 2019-03-27
WO2014072405A1 (en) 2014-05-15
EA201590705A1 (ru) 2016-05-31
ES2882282T3 (es) 2021-12-01
BR112015010283A2 (pt) 2017-07-11
EP2917351B1 (en) 2018-12-19
EP2917351A1 (en) 2015-09-16
MX366912B (es) 2019-07-30
ES2713166T3 (es) 2019-05-20
JP2015533511A (ja) 2015-11-26
CA2889767C (en) 2021-09-21
BR112015010283A8 (pt) 2021-07-06
TR201903066T4 (tr) 2019-03-21
EP3508579A1 (en) 2019-07-10
ES2848774T3 (es) 2021-08-11
EP3444352B1 (en) 2020-12-16
EP3444352A2 (en) 2019-02-20
JP6833785B2 (ja) 2021-02-24
CN105008539A (zh) 2015-10-28
SG11201503308XA (en) 2015-05-28
CA3125293A1 (en) 2014-05-15
AU2017279688B2 (en) 2019-11-14
US10973901B2 (en) 2021-04-13
AU2017279688A1 (en) 2018-01-18
AU2013343520B2 (en) 2017-09-28
US20150273043A1 (en) 2015-10-01
US20190076517A1 (en) 2019-03-14
IL238586A0 (en) 2015-06-30
JP2019030309A (ja) 2019-02-28
ZA201503097B (en) 2018-11-28
MX2015005797A (es) 2016-03-09
EP3508579B1 (en) 2021-06-30
CA2889767A1 (en) 2014-05-15
AU2013343520A1 (en) 2015-06-04
KR20150079964A (ko) 2015-07-08
JP6412875B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
CN105008539B (zh) 通过酶缀合在大肠杆菌中生产重组疫苗
Micoli et al. Glycoconjugate vaccines: current approaches towards faster vaccine design
JP6435583B2 (ja) 莢膜グラム陽性菌のバイオコンジュゲートワクチン
TWI751513B (zh) E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
JP2020114232A (ja) 改変型宿主細胞およびその使用
US12128096B2 (en) Immunogenic composition
JP2023531242A (ja) 改変Ｅｘｏｔｏｘｉｎ Ａタンパク質
CN113950524A (zh) 生产大肠杆菌o-抗原多糖的生物缀合物的方法、其组合物及其使用方法
JP2022514704A (ja) Ｏ結合型グリコシル化認識モチーフ
Duke et al. Development and immunogenicity of a prototype multivalent group B Streptococcus bioconjugate vaccine
US20220054632A1 (en) Modified carrier proteins for o-linked glycosylation
Yates et al. Bacterial glycoengineering as a biosynthetic route to customized glycomolecules
Wang et al. Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines
JP2024517754A (ja) Ｏ－結合型グリコシル化に十分な最小シークオン
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
WO2025172892A1 (en) Modified proteins and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180112

Address after: Belgium Sutter Rixon

Applicant after: GLAXOSMITHKLINE BIOLOGICALS S.A.

Address before: Swiss Shi Lilun

Applicant before: Glycovaxyn AG

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200417